

ASX Announcement

15 April 2026

ADDITIONAL INFORMATION: DANISH SUPPLY AGREEMENT

Sydney, Australia, Genetic Signatures Limited (ASX: GSS) ("Genetic Signatures" or "the Company") provides the following additional information in relation to its announcement of 15 April 2026 on the Danish supply agreement:

- Over a full twelve-month period, sales from the Hvidovre supply agreement are expected to represent approximately 6% of the Company's current sales. This is based on the estimated testing volumes pursuant to the agreement as a percentage of the Company's current annual testing volumes and agreed pricing, and is subject to general market and business assumptions.
- The Board considers the Agreement to be meaningful to the Company's operations. The Contract provides a meaningful, long term and recurring contribution to revenue in EMEA, diversifies the Company's customer base, and is consistent with the Company's growth strategy.
- As at the date of this announcement, the Contract is legally binding and there are no conditions precedent outstanding. On completion of customary installation and validation processes commercial orders are expected from September 2026.

Save as disclosed in this announcement and in the Company's prior ASX announcement dated 15 April 2026, the Company is not aware of any other material information relevant to assessing the impact of the Contract on the price or value of the Company's securities.

About Genetic Signatures Limited

Genetic Signatures Limited (ASX: GSS) is an Australian molecular diagnostics company focused on the development and commercialisation of molecular detection products for infectious diseases. The Company's proprietary 3base® technology platform simplifies the detection of pathogens, offering superior sensitivity and specificity across a broad range of clinical applications. Genetic Signatures markets its *EasyScreen*™ range of diagnostic assays globally, with a growing commercial presence across Europe, the United Kingdom, and the Asia-Pacific region.

Authorised for release by the Board of Genetic Signatures Limited

For further information, see our website (www.geneticsignatures.com) or contact us:

Daniel Ireland**Investor Relations**Daniel.ireland@datair.com.au

0428 607 884